- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01086553
9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease
October 29, 2014 updated by: Dr. Falk Pharma GmbH
Double-blind, Double-dummy, Randomised, Comparative, Multi-centre Phase III Study on the Efficacy and Tolerability of an 8-week Oral Treatment With 9 mg Budesonide Once Daily vs. 3 mg Budesonide Three-times Daily in Patients With Active Crohn's Disease
This study aims to evaluate the efficacy of 9 mg budesonide once daily (OD) versus 3 mg budesonide three-times daily (TID) for the induction of remission in Crohn's disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
471
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Frankfurt, Germany, 60431
- Med. Klinik I - Markus-Krankenhaus - Frankfurter Diakonie-Kliniken
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent,
- Age 18 to 75 years,
- Symptoms of Crohn's disease since at least 3 months; diagnosis confirmed by endoscopic and histological, or endoscopic and radiological criteria [endoscopy not older than 12 months or if older, then clinical signs (e.g., pain localisation, pain intensity, blood in stool) and behaviour (according to Montreal classification) should be unchanged compared to former episodes],
- Localisation of CD either in terminal ileum, coecum, ascending colon, or ileocolitis,
- Active phase of disease (200 < CDAI < 400),
- Negative pregnancy test in females of childbearing potential,
- Women of child-bearing potential have to apply appropriate contraceptive methods, e.g., hormonal contraception, intrauterine device (IUD), double-barrier method of contraception (e.g., use of a condom and spermicide), or partner has undergone vasectomy. The investigator is responsible for determining whether the subject has adequate birth control for study participation.
Exclusion Criteria:
- Known Crohn's lesions in the upper GI-tract (up to and including the jejunum) or rectum with present symptoms,
- Septic complications,
- Evidence of infectious diarrhoea (i.e., pathogenic bacteria in stool culture),
- Abscess, perforation, or active fistulas,
- Ileostomy or colostomy,
- Resection of more than 50 cm of the ileum,
- Bowel surgery within the last 3 months,
- Immediate surgery required (e.g., major stenosis, serious bleeding, peritonitis, ileus),
- Clinical signs of stricturing disease,
- Subileus within the last 6 months (subileus with inflammatory hint allowed),
- Suspicion of ileus, subileus or corresponding symptoms,
- Parenteral or tube feeding,
- Active peptic ulcer disease, local intestinal infection, or known established cataract,
- Diabetes mellitus, infection, osteoporosis, glaucoma, tuberculosis, or hypertension if careful medical monitoring is not ensured,
- Abnormal hepatic function (ALT or ALP > 2.5 x upper limit of normal [ULN]), liver cirrhosis, or portal hypertension,
- Abnormal renal function (Cystatin C > ULN),
- Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder,
- History of cancer in the last five years (except for non-metastatic cancers, e.g., basalioma),
- Treatment with immunosuppressants or anti-cancer drugs, e.g., 6 TG, methotrexate, tacrolimus, cyclophosphamide, or cyclosporine within the last 3 months; in case of treatment with azathioprine or 6 MP the drugs have to be used for maintenance of remission only and dosage has to be unchanged within the last 3 months before baseline visit and during the study,
- Treatment with ketoconazole or other CYP3A inhibitors within the last month before baseline visit,
- Treatment with anti-TNF-alpha therapy within 3 months before baseline visit,
- Conventional steroids (iv, po, rectal) within 2 weeks before baseline visit,
- > 6 mg/d budesonide po within 2 weeks before baseline visit,
- Steroids for inhalation within 2 weeks before baseline visit,
- Patients known to be steroid-refractory,
- Treatment of study disease with oral antibiotics (e.g., metronidazole or ciprofloxacin) within the last 2 weeks,
- Application of non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks before baseline visit except ≤ 350 mg/d or short-term acetylsalicylic acid (paracetamol is allowed),
- Known intolerance/hypersensitivity to study drug,
- Well-founded doubt about the patient's cooperation, e.g., because of addiction to alcohol or drugs,
- Existing or intended pregnancy or breast-feeding,
- Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
9mg budesonide OD
|
9mg budesonide OD
3mg budesonide TID
|
Active Comparator: B
3mg budesonide TID
|
9mg budesonide OD
3mg budesonide TID
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of clinical remission, defined as a CDAI < 150, at week 8 (LOCF)
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Response to treatment defined as CDAI < 150 or CDAI reduction of > 100 points
Time Frame: 8 weeks
|
8 weeks
|
Adverse events
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Axel Dignass, Prof., Med. Klinik I - Markus-Krankenhaus - Frankfurter Diakonie-Kliniken
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (Actual)
May 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
March 12, 2010
First Submitted That Met QC Criteria
March 12, 2010
First Posted (Estimate)
March 15, 2010
Study Record Updates
Last Update Posted (Estimate)
October 30, 2014
Last Update Submitted That Met QC Criteria
October 29, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Intestinal Diseases
- Inflammatory Bowel Diseases
- Crohn Disease
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Budesonide
Other Study ID Numbers
- BUG-2/CDA
- 2008-006957-42 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn´s Disease
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen UniversityRecruitingEndoscopic Recurrence Rate | After Ileocolic Crohn 's Disease SurgeryChina
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
-
Dr. Falk Pharma GmbHCompletedCrohn´s DiseaseGermany
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompletedUlcerative Colitis | Crohn´s DiseaseGermany
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Recruiting
Clinical Trials on budesonide
-
West Penn Allegheny Health SystemCompleted
-
University of MiamiAstraZenecaCompleted
-
Meir Medical CenterUnknown
-
Research in Real-Life LtdOrion Corporation, Orion PharmaCompleted
-
St. Paul's Hospital, CanadaUnknown
-
Aquilon Pharmaceuticals S.A.Completed
-
AstraZenecaCompleted
-
Dr. Falk Pharma GmbHCompletedEosinophilic EsophagitisGermany